Ubs Asset Management Americas Inc Halozyme Therapeutics, Inc. Transaction History
Ubs Asset Management Americas Inc
- $277 Billion
- Q1 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 160,954 shares of HALO stock, worth $8.37 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
160,954
Previous 161,180
0.14%
Holding current value
$8.37 Million
Previous $5.96 Million
9.9%
% of portfolio
0.0%
Previous 0.0%
Shares
26 transactions
Others Institutions Holding HALO
# of Institutions
442Shares Held
122MCall Options Held
216KPut Options Held
140K-
Black Rock Inc. New York, NY18.2MShares$949 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA13MShares$679 Million0.01% of portfolio
-
State Street Corp Boston, MA6.49MShares$337 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.12MShares$214 Million3.73% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.79MShares$197 Million0.24% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $7.24B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...